CHF 63.8
(-0.47%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 1.68 Billion CHF | 21.61% |
2022 | 1.38 Billion CHF | 6.57% |
2021 | 1.29 Billion CHF | 82.66% |
2020 | 710.88 Million CHF | 9.85% |
2019 | 647.14 Million CHF | 5.28% |
2018 | 614.7 Million CHF | 12.86% |
2017 | 544.65 Million CHF | 9.7% |
2016 | 496.5 Million CHF | 11.87% |
2015 | 443.83 Million CHF | 2.03% |
2014 | 435.01 Million CHF | -0.86% |
2013 | 438.77 Million CHF | -3.63% |
2012 | 455.3 Million CHF | -1.02% |
2011 | 460 Million CHF | 0.3% |
2010 | 458.64 Million CHF | -3.33% |
2009 | 474.43 Million CHF | 3.74% |
2008 | 457.31 Million CHF | 6.58% |
2007 | 429.06 Million CHF | -2.98% |
2006 | 442.23 Million CHF | 8.33% |
2005 | 408.21 Million CHF | 8.85% |
2004 | 375.01 Million CHF | 5.34% |
2003 | 355.99 Million CHF | 3.49% |
2002 | 343.99 Million CHF | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 1.72 Billion CHF | 0.0% |
2023 FY | 1.68 Billion CHF | 21.61% |
2023 Q4 | 1.68 Billion CHF | 0.0% |
2023 Q2 | 1.5 Billion CHF | 0.0% |
2022 FY | 1.38 Billion CHF | 6.57% |
2022 Q4 | 1.38 Billion CHF | 0.0% |
2022 Q2 | 1.26 Billion CHF | 0.0% |
2021 Q2 | 768.95 Million CHF | 0.0% |
2021 Q4 | 1.29 Billion CHF | 0.0% |
2021 FY | 1.29 Billion CHF | 82.66% |
2020 Q4 | 710.88 Million CHF | 0.0% |
2020 Q2 | 663.79 Million CHF | 0.0% |
2020 FY | 710.88 Million CHF | 9.85% |
2019 Q2 | 600.31 Million CHF | 0.0% |
2019 Q4 | 647.14 Million CHF | 0.0% |
2019 FY | 647.14 Million CHF | 5.28% |
2018 Q4 | 614.7 Million CHF | 0.0% |
2018 Q2 | 573.87 Million CHF | 0.0% |
2018 FY | 614.7 Million CHF | 12.86% |
2017 FY | 544.65 Million CHF | 9.7% |
2017 Q4 | 544.65 Million CHF | 0.0% |
2017 Q2 | 505.97 Million CHF | 0.0% |
2016 FY | 496.5 Million CHF | 11.87% |
2016 Q4 | 496.5 Million CHF | 0.0% |
2016 Q2 | 446.49 Million CHF | 0.0% |
2015 Q4 | 443.83 Million CHF | 0.0% |
2015 FY | 443.83 Million CHF | 2.03% |
2015 Q2 | 422.56 Million CHF | 0.0% |
2014 Q2 | 414.19 Million CHF | 0.0% |
2014 Q4 | 435.01 Million CHF | 0.0% |
2014 FY | 435.01 Million CHF | -0.86% |
2013 Q2 | 434.68 Million CHF | 0.0% |
2013 FY | 438.77 Million CHF | -3.63% |
2013 Q4 | 438.77 Million CHF | 0.0% |
2012 FY | 455.3 Million CHF | -1.02% |
2012 Q2 | 454.77 Million CHF | 0.0% |
2012 Q4 | 455.3 Million CHF | 0.0% |
2011 Q2 | 452.79 Million CHF | 0.0% |
2011 Q4 | 460 Million CHF | 0.0% |
2011 FY | 460 Million CHF | 0.3% |
2010 Q2 | 465.59 Million CHF | 0.0% |
2010 FY | 458.64 Million CHF | -3.33% |
2010 Q4 | 458.64 Million CHF | 0.0% |
2009 Q4 | 474.43 Million CHF | 0.0% |
2009 FY | 474.43 Million CHF | 3.74% |
2008 FY | 457.31 Million CHF | 6.58% |
2007 FY | 429.06 Million CHF | -2.98% |
2006 FY | 442.23 Million CHF | 8.33% |
2005 FY | 408.21 Million CHF | 8.85% |
2004 FY | 375.01 Million CHF | 5.34% |
2003 FY | 355.99 Million CHF | 3.49% |
2002 FY | 343.99 Million CHF | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Relief Therapeutics Holding AG | 76.39 Million CHF | -2103.011% |
Tecan Group AG | 2.07 Billion CHF | 18.857% |
Santhera Pharmaceuticals Holding AG | 109.62 Million CHF | -1435.068% |
Basilea Pharmaceutica AG | 173.28 Million CHF | -871.141% |
Siegfried Holding AG | 1.86 Billion CHF | 9.596% |
Molecular Partners AG | 198.35 Million CHF | -748.431% |